The drug is administered subcutaneously ... investigating treatments for people living with hemophilia. In April, the FDA approved Pfizer’s Beqvez, a one-time gene therapy for patients with ...

Pfizer’s Mylotarg is back ... after the FDA reapproved it in the aggressive blood cancer, acute myeloid leukaemia. The world’s first approved antibody-drug conjugate, where a targeted antibody ...

The company said the discontinuation was due to several reasons,” Reuters news service reported, “including limited interest ...

The U.S. Food and Drug Administration has approved ... with hemophilia because it can be administered less frequently than other existing options,” said Tanya Wroblewski, M.D., deputy director of the ...

WASHINGTON, D.C. — The U.S. Food and Drug ... FDA’s approval of Qfitlia was based on findings from two large multicenter, randomized clinical trials involving 177 male patients with hemophilia ...

The FDA has approved Baxter Healthcare's hemophilia B drug for use in patients aged 16 years of age and older in the United States. This approval represents the first new treatment for this ...

Sanofi SNY and partner, Alnylam Pharmaceuticals ALNY, announced that the FDA has approved ... similarly to other hemophilia treatments. The FDA has granted Qfitlia Orphan Drug Designation ...

"Today's approval ... in the FDA's Center for Drug Evaluation and Research. "This new treatment option highlights our continued efforts to improve the lives of patients with hemophilia." ...

The U.S. Food and Drug ... hemophilia B, with or without factor VIII or IX inhibitors. The FDA granted Qfitlia Orphan Drug and Fast Track designations for this application. The FDA granted the ...